Kinase Inhibitors Market To Gain Enhanced Demand From Pharmaceutical And Healthcare Industry Till 2022 | Million Insights

“Million Insights – World\’s Fastest Growing Market Research Database”
According to new report available with Million Insights, Kinase inhibitors are now considered to be the novel therapeutics. The factors identified which are driving the growth of the Kinase Inhibitors market are incidental rise of different types of cancer patients, rise in the aging population and increase in the focus to launch innovative medicines by the pharmaceutical companies.

In pharmaceutical sector, anti – cancer drugs form the most lucrative segment. From the past market trend it has shown that this anti – cancer drugs or kinase inhibitors has accounted over 10% of the global market. In the forecasted year of 2015 to 2022, Kinase Inhibitors Market CAGR is expected to witness a double digit growth. The factors identified which are driving the growth of the Kinase Inhibitors market are incidental rise of different types of cancer patients, rise in the aging population and increase in the focus to launch innovative medicines by the pharmaceutical companies. These key factors combined with competition from several pharmaceutical and oncology associations to paunch new product is propelling the growth of the market exponentially. Kinase inhibitors are basically a type of enzyme of protein base. Use of Kinase enzyme helps to shuffle the protein structure by the transfer of phosphates. These phosphates get collected from ATP. ATP is Adenosine Triphosphate. Kinase on protein bases has several functions. These functions includes regulating variety of cell cycles and their phases, cell differentiation, cell proliferation, and apoptosis. These functions helps to regulate various activities of cancerous cell.

Full Research Report On Global Kinase Inhibitors Market Analysis available at:

Kinase inhibitors are now considered to be the novel therapeutics. This is because these inhibitors are targeted to improve the patients survival rate by several preventive measures which will hinder the growth of tumors selectively as opposed to the classical chemo therapy which indiscriminate the cell death. Reports from American cancer association say that in the year 2014, the global sales for small molecule kinase inhibitors generated USD 18.49 billion of revenues for manufactures. This trend is expected to see a phenomenal growth till the forecast period of 2022. The sales growth is expected to exceed the wider cancer treating drug market in the upcoming years. This is because of huge expansion of kinase inhibitors in terms of clinical usage among stratified patient as an end user. Growth of this market is expected to improve by launch and uptake of the advanced version of breakthrough therapies such as a marketed product, imbruvica (Ibrutinib), candidate drugs pablociclib, Idelalisib and ABT – 199. Market trend also quotes that there will more incidental rise of cancerous patients in the upcoming years. These is validated mostly the global associations related to oncology treatment. So the manufactures for kinase inhibitors have a potential opportunity in the near future. This is mainly because the kinase inhibitors are are being considered as a key medication to prevent proliferation of cancerous cells. Most of the drugs which are going to be used to oncology treatment in clinical trials phase are expected to be launched in the next five to six years based on the strength of kinase activities of these drugs. However it has also been identified that healthcare cost containment issues and cost cutting in research funding are the major restraints for the growth of this market. For example, the cost of Tyrosin Kinase Inhibitors (TKI) was approximated to be USD 26400 in non pharmaceutical spending in the year 2012 as per American Cancer Society.

The global market for Kinase Inhibitors are segmented on the basis of types, by geography and by target end users. The target end users for this market are mainly pharmaceutical companies, private and government research institutes, healthcare institutes and academic institutes. By types the global market is further segmented into Tyrosine Kinase Inhibitors (TKI), Receptor Tyrosine Kinase Inhibitors which includes EGFR, PDGFR, VEGFR,HER2 which is a type of Non Receptor Tyrosine Kinase Inhibitor (RCTKI), BCR – ABL, Janus Kinase Inhibitor (JAK), Mesenchymal Epithelial Transition Growth Factor (c – MET), Speen Tyrosine Kinase (SYK) Inhibitors which is again further divided into classes such as Mulikinase Inhibitors, Threonine Kinase Inhibitors, m TOR Kinase Inhibitors, B RAFM, RHO Kinase Inhibitors, Cyclin Dependent Kinase Inhibitors, Aurora Kinase Inhibitors, MAP or MEK Kinase Inhibitors, JNK Inhibitors, Protein Kinase c Inhibitors, PI3K Inhibitors, others ( Monoclonal Antibody Kinase Inhibitors) which is again classified into Humanized Monoclonal Antibody, Chimeric Monoclonal Antibody, Humanized Monoclonal Antibody.

By geography the global market is segmented into major regions which include North America, Europe, Asia Pacific and rest of the world (R o W). As with other medicines for cancer the dominant countries for the growth of Kinase Inhibitor market are Japan, the European Union countries and the United States. These countries generate the highest revenue the Kinase Inhibitor market. However over the next five to six years this market is expected to see an exponential growth from BRIC countries. This is because of increase in the number of health insurances, healthcare reforms, and increase in the affluence segment from this region. In the forecasted period of 2015 to 2022 the first generation of Kinase Inhibitor drug is also expected to lose intellectual property which includes patents and trademarks protection and competition from low cost generic substitutes. This will temporarily restricted the expected expansion in many lucrative submarkets. The key players in Kinase inhibitors market are Bristol Meyers Squibb, Boehringer Ingelhgeim, Cytrx Corporation, Eisai Inc., Eton Bioscience Inc., Novartis International Ag, Glaxosmithkline, Merk Serona Sa, Osi Pharmaceuticals Llc., Pfizer. These major leaders face a stiff competition to retain their sustainable foothold in this market measured on different competitive market dynamics. For example Novartis’s Gleevec for leukemia treatment is amongst the best selling Kinase Inhibitors.

Request for Free Sample Copy at:

Market Segment:

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Kinase Inhibitors in these regions, from 2012 to 2022 (forecast), covering

• North America

• Europe

• China

• Japan

• Southeast Asia

• India

Global Kinase Inhibitors market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including

• Boehringer Ingelheim

• Cytrx Corporation

• Eton Bioscience Inc.

• Glaxosmithkline

• Bristol-Myers Squibb

• Osi Pharmaceuticals Llc

• Pfizer

• Eisai Inc.

• Merck Serono Sa

• Novartis International Ag

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

• Tyrosin Kinase Inhibitors (TKI)

• Receptor Tyrosine Kinase Inhibitors

• Non-Receptor Tyrosine Kinase Inhibitors

• Mulikinase Inhibitors

• Threonine Kinase Inhibitors

• mTOR Kinase Inhibitors

• RHO Kinase Inhibitors

• Cyclin Dependant Kinase Inhibitors

• Others

Related Reports of this Category available at Million Insights:

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Kinase Inhibitors for each application, including

• Pharmaceutical

• Health Care Products

• Scientific Research

About Million Insights
Million Insights, is a distributor of market research reports, published by premium publishers only. We have a comprehensive market place that will enable you to compare data points, before you make a purchase. Enabling informed buying is our motto and we strive hard to ensure that our clients get to browse through multiple samples, prior to an investment. Service flexibility & the fastest response time are two pillars, on which our business model is founded. Our market research report store, includes in-depth reports, from across various industry verticals, such as healthcare, technology, chemicals, food & beverages, consumer goods, material science & automotive.

For More Information:

Media Contact
Company Name: Million Insights
Contact Person: Ryan Manuel
Email: Send Email
Phone: 91-20-65300184
Address:Office No. 302, 3rd Floor, Manikchand Galleria, Model Colony, Shivaji Nagar
City: Pune
State: Maharashtra
Country: India